Two Directors at Anheuser-Busch In Bev SANV sold 32,000 shares at 80.010USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Constellium: very strong Q4 2025 results with the momentum continuing into H1 2026|Eramet publishes weak results for 2025 but takes radical measures to rapidly improve its financial structure, notably with a plan to strengthen its equity capital by € 500m|AF-KLM: Unit costs under control enabling good profitability levels|
Constellium: very strong Q4 2025 results with the momentum continuing into H1 2026|Eramet publie de faibles résultats 2025 mais prend des mesures radicales pour améliorer rapidement la structure financière, notamment avec un projet de renforcement des fonds propres de 500 m EUR|AF-KLM: Unit costs under control enabling good profitability levels|
AEGON: Uneventful results, US weaker, underlying OCG in line / Air France-KLM: Productivity gains starting to filter through / Arcadis: Weak revenues and EBITA, but strong NWC / Ascencio: Results in line, no concerns on Carrefour Belgium exposure / Azelis: Persisting softness in 4Q25, continued focus on costs and cash / BAM Group: Solid 2H25 results, 2026 outlook in line / Belgian telecoms: Telenet improved net adds, to relist as part of Ziggo in 2027, Liberty to sell half of its 66% Wyre stake ...
Whilst ABI's beer volumes have been impacted in the past three years by a mix of country-specific and broader affordability issues and possibly also a changing attitude towards alcohol consumption in some mature markets, we see green shoots and expect volume growth to resume this year, which should support investor sentiment. We still see ABI as the undisputed leader in the beer space, with leading market shares in many of the world's largest profit pools, ongoing digitization and premiumization...
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 February 19, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of th...
Company comments AB InBev: Little to disappoint Adyen: 2H25 results – mixed results, soft guidance CVC Capital Partners: Executing well dsm-firmenich: Messy results Fagron: Beat on all lines, confident FY26 outlook to drive c.5% consensus EBITDA upgrade Flow Traders: EMEA saves the day KBC: Good results, opening up “jaws” further to 2028 Kinepolis: Canadian peer Cineplex 4Q25 results below consensus, January 2026 box office revenue up MICC: FX headwind leads to a 50bp margin miss in FY25 Montea:...
4Q organic top line and EBITDA growth was slightly better than consensus. ABI FY26 guidance of 4-8% organic EBITDA growth is in line with the mid term guidance and our & consensus estimates at c. +5%. Total FY25 dividend is upped from € 1 to € 1.15, including an earlier interim dividend of € 0.15. We still see AB InBev as the undisputed leader in the beer market, with leading market shares in many markets, ongoing digitization and premiumization trends allowing to generate healthy free cash flow...
AB InBev is due to report its full year results on 12 February. We have adjusted our forecasts for the fourth quarter to account for weaker than previously expected volumes in North America, Brazil and China. We have also increased our 12-month target price from €56.18 to €66.20 but change our recommendation from Buy to HOLD.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.